iShares Core MSCI EAFE ETF
iShares · Tracks MSCI EAFE IMI Index · Inception Oct 18, 2012
Composite score
Based on a 0.070% expense ratio.
Based on $186.54B in net assets.
Top-10 holdings represent 11.4% of net assets.
International Developed base · ETF wrapper · 3.37% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IEFA in our tools
Tool · Cost
Compare IEFA's fee against another fund
Compounds the 0.070% expense ratio against a peer over decades.
Tool · Overlap
Compare IEFA's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar International Developed funds.
Tool · TLH
Find a tax-loss harvesting partner for IEFA
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ASML Holding N.V. | 2.21% |
| 2 | HSBC HOLDINGS PLC | 1.24% |
| 3 | ASTRAZENECA PLC | 1.16% |
| 4 | Roche Holding AG | 1.13% |
| 5 | Novartis AG | 1.11% |
| 6 | Nestle S.A. | 1.03% |
| 7 | SHELL PLC | 1.02% |
| 8 | Siemens Aktiengesellschaft | 0.89% |
| 9 | COMMONWEALTH BANK OF AUSTRALIA | 0.83% |
| 10 | Mitsubishi UFJ Financial Group, Inc. | 0.80% |
Compare IEFA with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IEFA at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.